| Literature DB >> 31487771 |
Sang-Yeon Lee1, Jeon Seong2, Young Ho Kim2.
Abstract
We compared the therapeutic efficacy of facial nerve decompression (FND) and conservative treatment in patients with Bell's palsy through a systematic review and meta-analysis. Primary database search was performed in PubMed, Medline, and Embase. After screening, 13 studies were assessed for their eligibility. Among them, seven studies employing either the House-Brackmann grading system (HBGS) or May's classification (modified HBGS) were selected for quantitative and qualitative analysis. Based on May's classification, the degree of recovery was classified into complete (HBGS I), fair (HBGS II-III), or failed (HBGS IV-VI) recovery. The outcomes were assessed between 6 and 12 months after surgery. The estimated pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random effects model. Cohorts were comprised of patients who underwent FND (n=202, 53.0%) and conservative treatments (n=179, 47.0%). In pooled analysis, the rate of complete recovery was significantly higher in the FND group than in the control group (OR, 2.06; 95% CI, 1.22 to 3.48; P=0.007) showing neither heterogeneity nor publication bias. Meanwhile, the rates of fair recovery (OR, 0.71; 95% CI, 0.42 to 1.21; P=0.208) and failed recovery (OR, 0.60; 95% CI, 0.22 to 1.67; P=0.327) in the FND group were similar to that in the control group. In subgroup analyses, there was no significant difference in the OR according to the operation timing and surgical approach. FND can be a possible treatment option for patients with complete Bell's palsy, especially for complete recovery, which provide insights on decision-making and outcome prediction. However, FND should be determined carefully given the risk of small study effects and possible complications.Entities:
Keywords: Bell Palsy; Facial Nerve Decompression; Meta-Analysis
Year: 2019 PMID: 31487771 PMCID: PMC6787481 DOI: 10.21053/ceo.2019.00535
Source DB: PubMed Journal: Clin Exp Otorhinolaryngol ISSN: 1976-8710 Impact factor: 3.372
Fig. 1.Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram outlining the study design. HBGS, House-Brackmann grading system.
Characteristics of excluded studies (ordered by study year)
| Study | Reason for exclusion |
|---|---|
| Aoyagi et al. (1988) [ | Outcome measures: the degree of facial nerve palsy recovery is evaluated by ENoG and cannot be changed to May’s classification. |
| Fisch et al. (1981) [ | Outcome measures: the degree of facial nerve palsy recovery is also evaluated by nerve degeneration as ENoG and cannot be changed to may's classification. |
| Adour et al. (1978) [ | Outcome measures: the degree of facial nerve palsy recovery was evaluated by a unique method of FPRP and FPRI. There was no change can be evaluated in may's classification. |
| Mcneill (1974) [ | Outcome measures: the degree of facial nerve paralysis was divided into acceptable and unacceptable; thereby, conversion to may's classification was impossible. |
| Mechelse et al. (1971) [ | Outcome measures: the degree of facial nerve palsy recovery was assessed by classifying the frontalis muscle, orbicularis oculi muscle orbicularis oris muscle from 0 to 5 in six stages, so that it could not be replaced with may's classification. |
| May et al. (1981) [ | Subjects: the presumed duplicate cohort, with subsequent studies published by the same author. |
ENoG, electroneurography; FPRP, facial paralysis recovery profile; FPRI, facial paralysis recovery index.
Demographics and clinical characteristics of enrolled studies
| Study/country | Study design | Age (yr, range) | No. of FND groups | No. of controls | Surgical indication | Evaluation grading | Treatment outcome |
|---|---|---|---|---|---|---|---|
| Li et al. (2016)/China [ | Quasi-RCT | 21–62 (median, 41.3) | 25 | 13 | HBGS V or VI CMAP degeneration >95% (based on EMG) | May’s classification (modified HBGS) | Recovery of facial function, postoperative complications |
| Kim et al. (2016)/Korea [ | Retrospective | FND: 18–76 (mean±SD, 48.5±17.4); control: 18–74 (mean±SD, 50.4±16.1) | 12 | 22 | Degeneration >90% (based on ENoG) | HBGS | Recovery of facial function, hearing threshold |
| No voluntery EMG | |||||||
| Yanagihara et al. (2001)/Japan [ | Retrospective | FND: 16–71 (mean±SD, 34.6±14.6); control: 16–84 (mean±SD, 55.1±17.9) | 58 | 43 | HBGS V or VI CMAP degengeration >95% (based on EMG) | HBGS | Recovery of facial function Postoperative, complications |
| Gantz et al. (1999)/USA, multicenter [ | Prospective | FND: 9–58 (mean, 32); control: 23–66 (mean, 47) | 34 | 36 | Degeneration >90% (based on ENoG) | HBGS | Recovery of facial function |
| No voluntary EMG within 2 weeks | |||||||
| Gantz et al. (1999)/USA, Iowa [ | Prospective | FND: 20–57 (mean, 41); control: 23–66 (mean, 47) | 7 | 11 | Degeneration >90% (based on ENoG) | HBGS | Recovery of facial function, postoperative complications |
| No voluntary EMG within 2 weeks | |||||||
| May et al. (1985)/USA [ | Prospective | NA | 25 | 13 | Complete paralysis (and) degeneration >90% (based on EMG) | HBGS | Recovery of facial function |
| Brown (1982)/Canada [ | Quasi-RCT | NA | 41 | 41 | Complete paralysis | May’s classification (modified HBGS) | Recovery of facial function, postoperative complications |
| Unfavorable prognosis for complete recovery[ |
FND, facial nerve decompression; RCT, randomized controlled trial; HBGS, House-Brackmann grading system; CMAP, compounding muscle action potential; EMG, electromyography; SD, standard deviation; ENoG, electroneurography; NA, not available.
Facial nerve function test showed function of less than 25% on the affected side.
Comparison of treatment outcomes between FND and conservative treatment
| Study/country | Approach | Surgical timing | Assessment timing (mo) | FND | Control | Side effect (FND) | ||
|---|---|---|---|---|---|---|---|---|
| Recovery of facial function HBGS | Recovery of facial function May’s classification | Recovery of facial function HBGS | Recovery of facial function May’s classification | |||||
| Li et al. (2016)/China [ | Transmastoid approach | >2 mo (delayed) | 12 | NA | (Total=25) Complete: 2, fair: 14, fail: 9 | NA | (Total=13) Complete: 1, fair: 6, fail: 6 | SNHL: 4/25, tinnitus: 3/25 |
| Kim et al. (2016)/Korea [ | Transmastoid approach | 42 day (21–70, delayed) | 6 (SD, 2.5) | (Total=12) I: 3, II: 6, III: 3, IV–VI: 0 | (Total=12) Complete: 3, fair: 9, fail: 0 | (Total=22) I: 5, II: 9, III: 4, IV: 3, V: 1 | (Total=22) Complete: 5, fair: 13, fail: 4 | Deterioration of hearing threshold (a mean of 9.7 dB) |
| Yanagihara et al. (2001)/Japan [ | Transmastoid approach | >14 day (delayed) | 12 | (Total=58) I: 26, II: 15, III: 17, IV–VI: 0 | (Total=58) Complete: 26, fair: 32, fail: 0 | (Total=43) I: 10, II: 16, III: 11, IV–V: 6 | (Total=43) Complete: 10, fair, 27, fail: 6 | Transient CHL |
| Gantz et al. (1999)/USA, multicenter [ | MFA | <14 day (early) | 7 | (Total=34) I: 14, II: 17, III: 2, IV: 1, V–VI: 0 | (Total=34) Complete: 14, fair: 19, fail: 1 | (Total=36) I: 5, II: 10, III: 19, IV: 2, V–VI: 0 | (Total=36) Complete: 5, fair: 29, fail: 2 | NA |
| Gantz et al. (1999)/USA, Iowa [ | MFA | >14 day (delayed) | 7 | (Total=7) I: 0, II: 2, III: 5, IV–VI: 0 | (Total=7) Complete: 0, fair: 7, fail: 0 | (Total=11) I: 0, II: 4, III: 7, IV–VI: 0 | (Total=11) Complete: 0, fair: 11, fail: 0 | CHL: 1/26, CSF leakage: 1/26 |
| May et al. (1985)/USA [ | Transmastoid approach | <14 day (early) | >6 | (Total=25) I: 0, II: 5, III: 11, IV: 9 | (Total=25) Complete: 0, fair: 16, fail: 9 | (Total=13) I: 1, II: 2, III: 9, IV: 1 | (Total=13) Complete: 1, fair: 11, fail: 1 | NA |
| Brown (1982)/Canada [ | Transmastoid approach | <14 day (early) | 6–12 | (Total=41) Complete: 25, fair: 10, fail: 6 | (Total=41) Complete: 20, fair: 12, fail: 9 | Deafness: 6/41, persistent giddiness: 2/41 | ||
FND, facial nerve decompression; HBGS, House-Brackmann grading system; NA, not available; SNHL, sensorineural hearing loss; SD, standard deviation; CHL, conductive hearing loss; MFA, middle fossa approach; CSF, cerebrospinal fluid.
Fig. 2.Comparison of the rate of complete recovery. (A) Forest plot comparing the rate of complete recovery between facial nerve decompression (experimental) and conservative treatment (control) using the odds ratio (OR) and 95% confidence interval (CI). Events represent the number of cases with complete recovery based on May’s classification. (B) Symmetry based on funnel plot suggesting no publication bias. (C) Sensitivity analysis.
Fig. 3.Comparison of the rate of fair and failed recovery. Forest plots comparing the rate of (A) fair recovery and (B) failed recovery between facial nerve decompression (experimental) and conservative treatment (control) using the odds ratio (OR) and 95% confidence interval (95% CI). Events were based on May’s classification.
Fig. 4.Comparison of the House-Brackmann grading scores. (A) Forest plot comparing the House-Brackmann grading scores between facial nerve decompression (experimental) and conservative treatment (control) based on the standardized mean difference (SMD). (B) Adjusted publication bias after applying the trim-and-fill method. SD, standard deviation; CI, confidence interval.
Fig. 5.Subgroup analyses according to operation timing. Forest plot comparing the recovery of facial nerve function according to the operation timing (early intervention: <14 days after onset vs. delayed intervention: >14 days after onset). (A) Complete recovery. (B) Fair recovery. (C) Failed recovery. OR, odds ratio; CI, confidence interval.
Fig. 6.Subgroup analyses according to surgical approach. Forest plot comparing the recovery of facial nerve function according to the surgical approach (transmastoid approach vs. middle fossa approach). (A) Complete recovery. (B) Fair recovery. (C) Failed recovery. OR, odds ratio; CI, confidence interval.